drugset

drugset / Trial / NCT00512317

Open-label Extension to Protocol 1042-0600

NCT00512317 ↗

Phase 2 Completed 123 enrolled Marinus Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

To allow open-label extension to patients who have completed Protocol 1042-0600.

Timeline

Start: 2007-06
Primary completion: 2009-12
Completion: 2013-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ganaxolone	Small molecule	—	—

Indications